SESSION TITLE: Lung Cancer
SESSION TYPE: Case Report Poster
PRESENTED ON: Sunday, April 17, 2016 at 11:45 AM - 12:45 PM
INTRODUCTION: It has been demonstrated that the ALK inhibitor Crizotinib can greatly improve survival among patients with ALK rearranged NSCLC.1,2 However, this outcome is limited to the patients with a good performance status and may not be representative of the outcomes in clinical practice. There are few reports on clinical experiences of the ALK rearranged NSCLC treatment.